ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib (see Figure 4), regarded as second second-generation tyrosine kinase inhibitor, was developed with an aim to overcome imatinib-resistant CML.We were first to report that nilotinib has inhibitory effect on the efflux function of ABCB1 and ABCG2 [93].